Tumor-colonizing bacteria: A potential tumor targeting therapy

Critical Reviews in Microbiology

Volumn 40, Issue 3, 2014, Pages 225-235

  Zu, Chao ^a   Wang, Jiansheng ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Antitumor vectors; Cancer therapy; Tumor; Tumor colonizing bacteria

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOKINE; PRODRUG;

BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIOLYSIS; BACTERIUM; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER THERAPY; DNA MODIFICATION; GENE CONTROL; GENE EXPRESSION; HUMAN; MULTIMODALITY CANCER THERAPY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SOLID TUMOR; TUMOR COLONIZING BACTERIUM; TUMOR MICROENVIRONMENT;

ANIMALS; BIFIDOBACTERIUM; BIOLOGICAL THERAPY; CLOSTRIDIUM; DISEASE MODELS, ANIMAL; HUMANS; METABOLIC ENGINEERING; NEOPLASMS;

EID: 84891099250     PISSN: 1040841X     EISSN: 15497828     Source Type: Journal    
DOI: 10.3109/1040841X.2013.776511     Document Type: Review

References (78)

1. Agorio C, Schreiber F, Sheppard M, et al. (2007). Live attenuated Salmonella as a vector for oral cytokine gene therapy in melanoma. J Gene Med 9:416-23. (Pubitemid 46796587)
2. Agrawal N, Bettegowda C, Cheong I, et al. (2004). Bacteriolytic therapy can generate a potent immune response against experimental tumors. Proc Natl Acad Sci USA 101:15172-7. (Pubitemid 39391737)
3. Al-Ramadi BK, Adeghate E, Mustafa N, et al. (2002). Cytokine expression by attenuated intracellular bacteria regulates the immune response to infection: the Salmonella model. Mol Immunol 38: 931-40. (Pubitemid 34496952)
4. Al-Ramadi BK, Fernandez-Cabezudo MJ, El-Hasasna H, et al. (2009). Potent anti-tumor activity of systemically-administered IL-2- expressing Salmonella correlates with decreased angiogenesis and enhanced tumor apoptosis. Clin Immunol 130:89-97.
5. Avogadri F, Martinoli C, Petrovska L, et al. (2005). Cancer immunotherapy based on killing of Salmonella-infected tumor cells. Cancer Res 65:3920-27. (Pubitemid 40616374)
6. Behnken S, Hertweck C. (2012). Cryptic polyketide synthase genes in non-pathogenic clostridium SPP. Plos One, 7:1-9.
7. Bettegowda C, Dang LH, Abrams R, et al. (2003). Overcoming the hypoxic barrier to radiation therapy with anaerobic bacteria. Proc Natl Acad Sci USA 100:15083-88. (Pubitemid 37518020)
8. Brown JM. (2007). Oxygen biology and hypoxia. San Diego: Elsevier Academic Press.
9. Cheng CM, Lu YL, Chuang KH, et al. (2008). Tumor-targeting prodrugactivating bacteria for cancer therapy. Cancer Gene Ther 15:393-401.
10. Clementz T, Zhou ZM, Raetz CRH. (1997). Function of the Escherichia coli msbB gene, a multicopy suppressor of htrB knockouts, in the acylation of lipid A - Acylation by MsbB follows laurate incorporation by HtrB. J Bio Chem 272:10353-60.
11. Cronin M, Sleator RD, Hill C, et al. (2008). Development of a luciferasebased reporter system to monitor Bifidobacterium breve UCC2003 persistence in mice. BMC Microbiol 8:1-12.
12. Dang LH, Bettegowda C, Huso DL, et al. (2001). Combination bacteriolytic therapy for the treatment of experimental tumors. Proc Natl Acad Sci U. S. A. 98:15155-60. (Pubitemid 34013985)
13. Dewhirst MW, Cao Y, Moeller B. (2008). Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 8:425-37. (Pubitemid 351744964)
14. Hauteville H, Khan S, Maskell DJ, et al.(2002) Two msbB genes encoding maximal acylation of lipid A are required for invasive Shigella flexneri to mediate inflammatory rupture and destruction of the intestinal epithelium. J Immunol 168:5240-51. (Pubitemid 34495992)
15. Dinarello CA, Gelfand JA, Wolff SM. (1993). Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. J Am Med Assoc 269:1829-35. (Pubitemid 23097351)
16. Eisenstein TK. (2001). Implications of Salmonella-induced nitric oxide (NO) for host defense and vaccines: NO, an antimicrobial, antitumor, immunosuppressive and immunoregulatory molecule. Microbes Infect 3:1223-31. (Pubitemid 34033757)
17. Engelbart K, Gericke D. (1964). Oncolysis by clostridia.V. Transplanted tumors of hamster. Cancer Res, 24:239-43.
18. Forbes NS. (2006). Profile of a bacterial tumor killer. Nat Biotechnol 24: 1484-85. (Pubitemid 44967465)
19. Fox ME, Lemmon MJ, Mauchline ML. (1996). Anaerobic bacteria as a delivery system for cancer gene therapy: in vitro activation of 5-fluorocytosine by genetically engineered clostridia. Gene Ther 3: 173-8. (Pubitemid 26117427)
20. Fu GF, Li X, Hou YY, et al. (2005). Bifidobacterium longum as an oral delivery system of endostatin for gene therapy on solid liver cancer. Cancer Gene Ther 12:133-40. (Pubitemid 40205095)
21. Fujimori M. (2006). Genetically engineered bifidobacterium as a drug delivery system for systemic therapy of metastatic breast cancer patients. Breast Cancer 13:27-31.
22. Ganai S, Arenas RB, Forbes NS. (2009). Tumor-targeted delivery of TRAIL using Salmonella typhimurium enhances breast cancer survival in mice. Brit J Cancer 101:1683-91.
23. Gericke D, Engelbart K. (1964). Oncolysis by clostridia. 2. Experiments on tumor spectrum with variety of clostridia in combination with heavy metal. Cancer Res 24:217-21.
24. Groot AJ, Mengesha A, van der Wall E, et al. (2007). Functional antibodies produced by oncolytic clostridia. Biochem Bioph Res 364: 985-9. (Pubitemid 350087897)
25. Hazlehurst LA, Landowski TH, Dalton WS. (2003). Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death. Oncogene 22: 7396-402. (Pubitemid 37487165)
26. Heppner F, Mose JR. (1978). Liquefaction (oncolysis) of malignant gliomas by a non pathogenic clostridium. Acta Neurochirurgica 42: 123-5. (Pubitemid 8377876)
27. Hertweck C. (2009). The biosynthetic logic of polyketide diversity. Angew Chem Int Edit 48:4688-716.
28. Jain RK. (2001). Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliver Rev 46:149-68.
29. Jia H, Li Y, Zhao T, et al. (2012). Antitumor effects of Stat3-siRNA and endostatin combined therapies, delivered by attenuated Salmonella, on orthotopically implanted hepatocarcinoma. Cancer Immunol Immun 61:1977-87.
30. Jiang SN, Phan TX, Nam TK, et al. (2010). Inhibition of tumor growth and metastasis by a combination of Escherichia coli-mediated cytolytic therapy and radiotherapy. Mol Ther 18:635-42.
31. Jiang ZM, Zhao P, Zhou ZH, et al. (2007). Using attenuated Salmonella typhi as tumor targeting vector for MDR1 siRNA delivery - an experimental study. Cancer Biol Ther 6:555-60. (Pubitemid 47328330)
32. Kasinskas RW, Forbes NS. (2006). Salmonella typhimurium specifically chemotax and proliferate in heterogeneous tumor tissue in vitro. Biotechnol Bioeng 94:710-21. (Pubitemid 44014201)
33. Kimura H, Zhang L, Zhao M, et al. (2010). Targeted therapy of spinal cord glioma with a genetically modified Salmonella typhimurium. Cell Proliferat 43:41-8.
34. Kopp-Hoolihan L. (2001). Prophylactic and therapeutic uses of probiotics: a review. J Am Diet Assoc 101:229-41. (Pubitemid 33712118)
35. Krick EL, Sorenmo KU, Rankin SC, et al. (2012). Evaluation of Clostridium novyi-NT spores in dogs with naturally occurring tumors. Am J Vet Res 73:112-18.
36. Lee CH, Wu CL, Shiau AL. (2008). Salmonella choleraesuis as an anticancer agent in a syngeneic model of orthotopic hepatocellular carcinoma. Int J Cancer 122:930-35.
37. Lee CH, Wu CL, Shiau AL. (2005). Systemic administration of attenuated Salmonella choleraesuis carrying thrombospondin-1 gene leads to tumor-specific transgene expression, delayed tumor growth and prolonged survival in the murine melanoma model. Cancer Gene Ther 12:175-84.
38. Li ZJ, Zhu H, Ma BY, et al. (2012). Inhibitory effect of Bifidobacterium infantis-mediated sKDR prokaryotic expression system on angiogenesis and growth of Lewis lung cancer in mice. BMC Cancer 12:1-12.
39. Li ZY, Fallon J, Mandeli J, et al. (2008). A genetically enhanced anaerobic bacterium for oncopathic therapy of pancreatic cancer. J Nat Cancer Inst 100:1389-400.
40. Liu SC, Ahn GO, Kioi M, et al. (2008). Optimized Clostridium-directed enzyme prodrug therapy improves the antitumor activity of the novel DNA cross-linking agent PR-104. Cancer Res 68:7995-8003.
41. Liu T, Chopra AK. (2010). An enteric pathogen Salmonella enterica serovar Typhimurium suppresses tumor growth by downregulating CD44(high) and CD4T regulatory (T-reg) cell expression in mice: the critical role of lipopolysaccharide and Braun lipoprotein in modulating tumor growth. Cancer Gene Ther 17:97-108.
42. Liu Y, Zhou M, Luo D. (2012). Bacteria-mediated in vivo delivery of quantum dots into solid tumor. Biochem Bioph Res Co 425: 769-74.
43. Loeffler M, Le?Negrate G, Krajewska M, Reed JC. (2008a). IL- 18-producing Salmonella inhibit tumor growth. Cancer Gene Ther 15: 787-94.
44. Loeffler M, Le?Negrate G, Krajewska M, Reed JC. (2008b). Inhibition of tumor growth using Salmonella expressing Fas ligand. J Nat Cancer Inst 100:1113-16.
45. Loeffler M, Le?Negrate G, Krajewska M, Reed JC. (2009). Salmonella typhimurium engineered to produce CCL21 inhibit tumor growth. Cancer Immunol Immun 58:769-75.
46. Loeffler M, Le?Negrate G, Krajewska M, Reed JC. (2007). Attenuated Salmonella engineered to produce human cytokine LIGHT inhibit tumor growth. Proc Natl Acad Sci USA 104:12879-83. (Pubitemid 47255248)
47. Low KB, Ittensohn M, Le T, et al. (1999). Lipid A mutant Salmonella with suppressed virulence and TNF α induction retain tumortargeting in vivo. Nat Biotechnol 17:37-41. (Pubitemid 29037207)
48. Maciag PC, Radulovic S, Rothman J. (2009). The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix. Vaccine 27:3975-83.
49. Maeda T, Murata M, Chiba H, et al. (2012). Claudin-4-targeted therapy using Clostridium perfringens enterotoxin for prostate cancer. Prostate 72:351-60.
50. Malik U, Mohiuddin M. (2002). External-beam radiotherapy in the management of liver metastases. Semin Oncol 29:196-201. (Pubitemid 34297291)
51. Minton NP, Mauchline ML, Lemmon MJ, et al. (1995). Chemotherapeutic tumor targeting using clostridial spores. Fems Microbiol Rev 17:357-64.
52. Morse SS. (1992). Evolving views of viral evolution - towards an evolutionary biology of viruses. Hist Phil Life Sci 14:215-48.
53. Nemunaitis J, Cunningham C, Senzer N, et al. (2003). Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients. Cancer Gene Ther 10:737-44. (Pubitemid 37243794)
54. Nguyen VH, Kim HS, Ha JM, et al. (2010). Genetically engineered Salmonella typhimurium as an imageable therapeutic probe for cancer. Cancer Res 70:18-23.
55. Nuyts S, Van Mellaert L, Theys J, et al. (2001). Radio-responsive recA promoter significantly increases TNF alpha production in recombinant clostridia after 2 Gy irradiation. Gene Ther 8:1197-201. (Pubitemid 32776394)
56. Pawelek JM, Low KB, Bermudes D. (2003). Bacteria as tumor-targeting vectors. Lancet Oncol 4:548-56.
57. Pawelek JM, Low KB, Bermudes D. (1997). Tumor-targeted Salmonella as a novel anti-cancer vector. Cancer Gene Ther 4:4537-44. (Pubitemid 27441058)
58. Ryan RM, Green J, Williams PJ, et al. (2009). Bacterial delivery of a novel cytolysin to hypoxic areas of solid tumors. Gene Ther 16: 329-39.
59. Saccheri F, Pozzi C, Avogadri F, et al. (2010). Bacteria-induced gap junctions in tumors favor antigen cross-presentation and antitumor immunity. Sci Transl Med 2:1-11.
60. Smedley III JG,, Uzal FA, McClane BA. (2007). Identification of a prepore large-complex stage in the mechanism of action of Clostridium perfringens enterotoxin. Infect Immun 75:2381-90. (Pubitemid 46744328)
61. St Jean AT, Zhang MM, Forbes NS. (2008). Bacterial therapies: completing the cancer treatment toolbox. Curr Opin Biotech 19: 511-17.
62. Stritzker J, Weibel S, Hill PJ, et al. (2007). Tumor-specific colonization, tissue distribution, and gene induction by probiotic Escherichia coli Nissle 1917 in live mice. Intl J Med Microbiol 297: 151-62. (Pubitemid 46678925)
63. Tang W, He YF, Zhou SC, et al. (2009). A novel Bifidobacterium infantis-mediated TK/GCV suicide gene therapy system exhibits antitumor activity in a rat model of bladder cancer. J Exp Clin Canc Res 28:1-7.
64. Thiele EH, Boxer GE, Arison RN. (1964). Oncolysis by clostridia. 4. Effect of nonpathogenic clostridial spores in normal ? pathological tissues. Cancer Res 24:234-8.
65. Toso JF, Gill VJ, Hwu P, et al. (2002). Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clinl Oncol 20:142-52. (Pubitemid 34032605)
66. van den Broeke LT, Daschbach E, Thomas EK, et al. (2003). Dendritic cell-induced activation of adaptive and innate antitumor immunity. J Immunol 171:5842-52. (Pubitemid 37467201)
67. Wachsberger P, Burd R, Dicker AP. (2003). Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin Cancer Res 9:1957-71. (Pubitemid 36687614)
68. Walther W, Petkov S, Kuvardina ON, et al. (2012). Novel Clostridium perfringens enterotoxin suicide gene therapy for selective treatment of claudin-3- and -4-overexpressing tumors. Gene Ther 19:494-503.
69. Wang R, Zhang XW, Wang GQ, et al. (2006). Systemic inhibition of tumor growth by soluble Flk-1 gene therapy combined with cisplatin. Cancer Gene Ther 13:940-7. (Pubitemid 44373794)
70. Xiang SL, Fruehauf J, Li CJ. (2006). Short hairpin RNA-expressing bacteria elicit RNA interference in mammals. Nat Biotechnol 24: 697-702. (Pubitemid 43882121)
71. Yam C, Zhao M, Hayashi K, et al. (2010). Monotherapy with a tumortargeting mutant of S. typhimurium inhibits liver metastasis in a mouse model of pancreatic cancer. J Surg Res 164:248-55.
72. Yazawa K, Fujimori M, Amano J, et al. (2000). Bifidobacterium longum as a delivery system for cancer gene therapy: selective localization and growth in hypoxic tumors. Cancer Gene Ther 7:269-74. (Pubitemid 30194562)
73. Yazawa K, Fujimori M, Nakamura T, et al. (2001). Bifidobacterium longum as a delivery system for gene therapy of chemically induced rat mammary tumors. Breast Cancer Res 66:165-70. (Pubitemid 32521423)
74. Zhang L, Gao LF, Zhao LJ, et al. (2007). Intratumoral delivery and suppression of prostate tumor growth by attenuated Salmonella enterica serovar typhimurium carrying plasmid-based small interfering RNAs. Cancer Res 67:5859-64. (Pubitemid 46985020)
75. Zhao M, Yang M, Li XM, et al. (2005). Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. Proc Natl Acad Sci USA 102:755-60. (Pubitemid 40282738)
76. Zhao M, Yang M, Ma HY, et al. (2006). Targeted therapy with a Salmonella typhimurium leucine-arginine auxotroph cures orthotopic human breast tumors in nude mice. Cancer Res 66:7647-52. (Pubitemid 44289222)
77. Zhu H, Li Z, Mao S, et al. (2011). Antitumor effect of sFlt-1 gene therapy system mediated by Bifidobacterium infantis on Lewis lung cancer in mice. Cancer Gene Ther 18:884-96.
78. Zhu LP, Yin Y, Xing J, et al. (2009). Therapeutic efficacy of Bifidobacterium longum-mediated human granulocyte colonystimulating factor and/or endostatin combined with cyclophosphamide in mouse-transplanted tumors. Cancer Sci 100:1986-90.